These findings demonstrate that RRx-001 triggers disulfidptosis in HCC by targeting the G6PD-NADPH axis while concurrently inducing ICD, achieving dual metabolic and immunomodulatory effects. Here, G6PD is linked to hepatocellular carcinoma.